CONFIRM anti-Melanosome (HMB45) Mouse Monoclonal Primary Antibody

Skip to Content

Skip over Generic Navigation

  • Select your country:
DIAGNOSTICS F. Hoffmann-La Roche Ltd

CONFIRM anti-Melanosome (HMB45) Mouse Monoclonal Primary Antibody

CONFIRM anti-Melanosome (HMB45) Mouse Monoclonal Primary Antibody, melanoma, 100x
Catalog Number:790-4366
Ordering Code:05479282001
Quantity:50 tests
Controls:Melanoma, Skin
Clone Name:HMB45
Regulatory Status:IVD

This antibody is intended for in vitro diagnostic use. Ventana Medical Systems, Inc. (Ventana) CONFIRM anti-Melanosome (HMB45) is a mouse monoclonal antibody (IgG1, kappa) directed against an oncofetal antigen present within immature melanosomes in the cytoplasm of activated and neoplastic melanocytes. CONFIRM anti-Melanosome (HMB45) is intended for laboratory use to qualitatively detect, via light microscopy, cells containing immature melanosomes in sections of formalin fixed, paraffin embedded tissue following staining on a Ventana automated slide stainer. The clinical interpretation of any staining, or the absence of staining, must be complemented by morphological studies and evaluation of proper controls. Evaluation must be made by a qualified pathologist within the context of the patient’s clinical history and other diagnostic tests.

Health Care Provider Notice
This website is intended for healthcare professionals only.

The content on this website is intended for healthcare professionals only. Information intended for the general public can be found on Please confirm that you are a medical professional before accessing the content of this website.

Yes, I hereby certify that I am a healthcare professional. Continue
Third-Party Link Disclosure
Disclosure for Links to Third-Party Websites

You are now leaving the Roche website. The site you are about to visit is operated by third-parties. The link to this site neither makes nor implies any representation or warranty for any products or services offered on a third-party site and is intended only to enable convenient access to the third-party site and for no other purpose.